A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Is This Study For You?

Let's Get Started!




Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Sharon Poisson

Sharon Poisson

Study ID

Protocol Number: 23-0053

More information available at ClinicalTrials.gov: NCT05702034

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers